Dyne Therapeutics, Inc. Common Stock

Day range

$15.53 – $16.02

Open

$15.64

Prev close

$15.62

Volume

1.74M

Market cap

$2.92B

Shares out

186.75M

P/E

—

P/S

—

P/B

4.15

P/FCF

—

ROE

-74.0%

ROA

-52.3%

Debt/Equity

0.30

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 29, 2026

  On September 29, 2026, the Company issued a press release and presentation announcing additional one-year clinical data from the ACHIEVE trial evaluating z-basivarsen in individuals with DM1. The data included sustained improvements in myotonia, function, muscle strength, and patient-reported outcomes, as well as updated safety and tolerability data.

• Public offeringJul 22, 2026

  On July 21, 2026, Dyne Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and Jefferies LLC, as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of 18,300,000 shares (the "Underwritten Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"). The public offering price of the Underwritten Shares is $20.50 per share, and the Underwriters have agreed to purchase the Underwritten Shares from the Company pursuant to the Underwriting Agreement at a price of $19.27 per share.

• Regulatory decisionJul 20, 2026

  On July 20, 2026, Dyne Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has accepted for review its biologics license application ("BLA") for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy ("DMD") amenable to exon 51 skipping. The FDA has granted the BLA Priority Review and assigned a Prescription Drug User Fee Act target action date of January 21, 2027.

• Director appointmentJun 22, 2026

  On June 22, 2026, the Board of Directors (the "Board") of Dyne Therapeutics, Inc. (the "Company"), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company's 2027 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. The Board has determined that Mr. Greene is an "independent" director under the Nasdaq Stock Market rules.

• Credit facilityJun 17, 2026

  On June 16, 2026, Dyne Therapeutics, Inc. entered into the Second Amendment to its Loan and Security Agreement with Hercules Capital, Inc. The Second Amendment expanded the debt facility to an aggregate of up to $400.0 million by adding two additional tranches of $50.0 million each and increasing the final tranche by $25.0 million, and reduced the minimum cash covenant under the Loan Agreement.

Days to cover

9.0

Short interest

25.98M

Avg volume

2.88M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
  positiveGlobeNewswire Inc.· Jul 21, 2026
• Dyne Therapeutics Announces Proposed Public Offering of Common Stock
  positiveGlobeNewswire Inc.· Jul 21, 2026
• Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
  neutralThe Motley Fool· Jun 26, 2026
• Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
  positiveThe Motley Fool· May 30, 2026
• Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
  positiveGlobeNewswire Inc.· May 26, 2026